Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by <i>In Situ</i> Silencing of Programmed-Death Ligands.

Versteven, Maarten; Flumens, Donovan; Campillo-Davó, Diana; De Reu, Hans; Van Bruggen, Laura; Peeters, Stefanie; Van Tendeloo, Viggo; Berneman, Zwi; Dolstra, Harry; Anguille, Sébastien; Hobo, Willemijn; Smits, Evelien; Lion, Eva

Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands.

Versteven, Maarten; Flumens, Donovan; Campillo-Davó, Diana; De Reu, Hans; Van Bruggen, Laura; Peeters, Stefanie; Van Tendeloo, Viggo; Berneman, Zwi; Dolstra, Harry; Anguille, Sébastien; Hobo, Willemijn; Smits, Evelien; Lion, Eva.

Afiliação

Versteven M; Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Flumens D; Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Campillo-Davó D; Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
De Reu H; Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Van Bruggen L; Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Peeters S; Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Van Tendeloo V; Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Berneman Z; Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Dolstra H; Division of Hematology, Antwerp University Hospital, Edegem, Belgium.
Anguille S; Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium.
Hobo W; Department of Laboratory Medicine - Laboratory of Hematology, Radboud University Medical Center, Nijmegen, Netherlands.
Smits E; Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Lion E; Division of Hematology, Antwerp University Hospital, Edegem, Belgium.

Front Immunol ; 13: 734256, 2022.

Article em En | MEDLINE | ID: mdl-35250967

Assuntos

Antígeno B7-H1; Vacinas Anticâncer; Células Dendríticas; Neoplasias; Proteína 2 Ligante de Morte Celular Programada 1; Antígeno B7-H1/genética; Linfócitos T CD8-Positivos; Vacinas Anticâncer/genética; Vacinas Anticâncer/metabolismo; Células Dendríticas/imunologia; Humanos; Interleucina-15/genética; Neoplasias/patologia; Proteína 2 Ligante de Morte Celular Programada 1/genética

Palavras-chave

Wilms' tumor 1 (WT1); dendritic cells; interleukin-15; programmed death (PD)-1; programmed death 1 ligand; siRNA

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Células Dendríticas / Vacinas Anticâncer / Antígeno B7-H1 / Proteína 2 Ligante de Morte Celular Programada 1 / Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google